JIUQUAN, China, Oct. 13, 2021
/PRNewswire/ -- Qilian International Holding Group
Limited (Nasdaq: QLI) (the "Company"), a China-based
pharmaceutical and chemical products manufacturer, announced
that on September 14, 2021, through its subsidiary Gansu
Qilianshan Pharmaceutical Co., Ltd. (the "Gansu
QLS"), it has received
Certificate of a Pharmaceutical Product (the "Export Certificate")
from Gansu Province Drug Administration, which approves the export
of its Qilian Shan® Oxytetracycline APIs (Active
Pharmaceutical Ingredients) (the "API") to Egypt.
The Export Certificate indicates that the Company's API
is a registered pharmaceutical product approved by
China, complies with relevant
standards of China,
is licensed for sale in Chinese market and is not subject to
any export restrictions. Moreover, the
product is licensed for use, and has already been used in
the Egyptian market. The production facilities and operations
also conform to the requirements of China's GMP.
Gansu QLS was established in 2006, and has grown to include
the development, manufacture and sale of more than
20 pharmaceutical products, which includes three major
ones, licorice products, oxytetracycline products, and
Traditional Chinese Medicine Derivatives (TCMD). These
products have been sold to more than 20 provinces across
China. Its oxytetracycline
products also comply with the National Medical Products
Administration (NMPA) certification, making it a strength of the
company. In terms of revenue structure, oxytetracycline
are main revenue sources of the Company. In recent performance
periods, oxytetracycline and licorice products have
contributed more than 60% of the Company's revenue, while
oxytetracycline products have accounted for more than 90% of
the sales of this segment and it is the Company's core
product.
Mr. Zhanchang Xin, Chairman and CEO of the Company, commented,
"We are very pleased with this good news. The approval of this
direct exporting license marks a smooth opening
to overseas markets. So that we have a solid foundation for
further export expansion in the future."
About Qilian International Holding Group Limited
Qilian International Holding Group Limited, headquartered
in Gansu, China, is a
pharmaceutical and chemical products manufacturer in China. It
focuses on the development, manufacture, marketing and sale of
licorice products, oxytetracycline products, traditional Chinese
medicine derivatives product, heparin product, sausage casings, and
fertilizers. The Company's products are sold in more than 20
provinces in China. For more information, visit the company's
website at http://qilianinternational.com/
Forward-Looking Statements
This announcement contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All statements other than statements
of historical fact in this announcement are forward-looking
statements. These forward-looking statements involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, financial
needs and the successful construction of the pig by-product
processing project facility. Investors can identify these
forward-looking statements by words or phrases such as "may,"
"will," "expect," "anticipate," "aim," "estimate," "intend,"
"plan," "believe," "potential," "continue," "is/are likely to" or
other similar expressions. The Company undertakes no obligation to
update forward-looking statements to reflect subsequent occurring
events or circumstances, or changes in its expectations, except as
may be required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect
its future results in the Company's registration statement and
in its other filings with the SEC.
For more information, please contact:
Qilian International Holding Group Limited
Email: QLI@qlsyy.net
View original
content:https://www.prnewswire.com/news-releases/qilian-international-holding-group-limited-received-approval-for-oxytetracycline-api-export-to-egypt-301398838.html
SOURCE Qilian International Holding Group Limited